ARCHIVES

As Bristol’s Final Defenses Fall, IVAX Prepares Launch Of Generic Paclitaxel.

This article is from The Cancer Letter archive.

Vol. 26 No. 38 | October 20, 2000

Download PDF Visit The Full Archive

Related Articles

ODAC Recommendation for Pertuzumab Signals FDA’s Resolve In Granting Accelerated Approvals

September 20, 2013

Long-Term Results Find Cisplatin Improves Survival

May 25, 2007

Concept Approval Given To $7 Million In OD Recompetitions, Renewals

May 28, 1982

Biomarker Identified Predicting Graft-Versus-Host Disease Risk

August 30, 2013

AIDS Biological Specimens Available From NIH

November 22, 1985

In Brief: Thomas Jordan Promoted At Bristol-Myers, Markison To Succeed Him In Oncology Div.

February 28, 1992